Welcome to our dedicated page for Neuphoria Therapeutics news (Ticker: NEUP), a resource for investors and traders seeking the latest updates and insights on Neuphoria Therapeutics stock.
Neuphoria Therapeutics Inc (NEUP) is a clinical-stage biotechnology company developing innovative treatments for neuropsychiatric disorders through advanced receptor modulation science. This page serves as the definitive source for verified news and official announcements related to their therapeutic pipeline, strategic partnerships, and clinical progress.
Investors and industry professionals will find timely updates on clinical trial milestones, regulatory developments, and financial disclosures. The curated collection includes press releases about their lead candidate BNC210 for anxiety disorders, research collaborations with major pharmaceutical partners, and scientific advancements in neuroscience.
All content undergoes strict verification to ensure accuracy and compliance with financial reporting standards. Users can expect regular updates covering key aspects of NEUP's operations including trial result announcements, intellectual property developments, and strategic business decisions that impact the neuropsychiatric treatment landscape.
Bookmark this page for direct access to primary source materials from Neuphoria Therapeutics, ensuring you stay informed about critical developments in this innovative biotech company's journey to address unmet mental health needs.
Neuphoria (NASDAQ: NEUP) said it will continue a robust strategic alternatives review and urged stockholders to vote for its nominees on the WHITE proxy card on Dec 4, 2025. The company paused R&D spending for BNC210 in PTSD while evaluating options and says it has received multiple indications of interest, including nearly a dozen advanced to NDAs and separate process letters. Neuphoria characterized Lynx1’s revised unsolicited bid of $4.75 per share as reduced, near cash value, and not reflecting licensing agreements that generated tens of millions in revenue. The Board said it will review Lynx1’s proposal alongside other offers and warned electing dissident nominees could jeopardize an independent review.
Neuphoria (Nasdaq: NEUP) announced the initiation of a strategic review to maximize stockholder value and has engaged H.C. Wainwright & Co. as exclusive financial advisor.
On November 10, 2025, the company received an unsolicited non-binding indication of interest from Lynx1 Master Fund LP to acquire outstanding shares for $5.20 per share in cash and to nominate directors for election at the Company’s 2025 Annual Meeting. The Board said it will evaluate this proposal with its advisors and confirmed there is no defined timeline and no assurance a transaction will occur.
The 2025 Annual Meeting date is now December 12, 2025; record date remains October 15, 2025. Stockholders are not required to take any action at this time.
Neuphoria Therapeutics (Nasdaq: NEUP) adopted a limited-duration stockholder rights plan effective October 27, 2025 to protect the integrity of its strategic review process.
The Board declared a dividend of one preferred share purchase right per outstanding common share as of the October 27, 2025 record date. Rights become exercisable if any person, entity or group acquires beneficial ownership of 15% or more of outstanding common stock without Board approval. Rights expire on October 27, 2026 unless earlier redeemed or exchanged. Existing holders at or above the threshold are grandfathered at current levels but cannot increase ownership without triggering the plan. Additional details will be filed on a Form 8-K.
Neuphoria Therapeutics (Nasdaq: NEUP) announced on October 20, 2025 that the AFFIRM-1 Phase 3 trial of BNC210 for acute treatment of social anxiety disorder (SAD) did not meet its primary endpoint or secondary endpoints.
The company said safety and tolerability remained favorable. Neuphoria will discontinue the SAD program, begin a strategic review of its portfolio and operations, and evaluate BNC210 for PTSD given prior positive chronic-dosing data. Neuphoria expects to provide an update by year-end.
The company highlighted a partnership with Merck (Merck-funded MK-1167 Phase 2 in Alzheimer’s) with up to $450 million of potential milestone payments plus royalties. As of June 30, 2025 cash and equivalents were $14.2 million, sufficient to fund operations through Q2 2027.
Neuphoria Therapeutics (NASDAQ:NEUP), a clinical-stage biotech company, has announced its fiscal year 2025 financial results and provided significant clinical updates. The company has achieved the Last Patient Last Visit (LPLV) milestone in its AFFIRM-1 Phase 3 trial of BNC-210 for social anxiety disorder (SAD), with topline data expected in early Q4 2025.
Financial highlights include a cash position of $14.2 million as of June 30, 2025, extending runway through Q2 2027. The company reported reduced R&D expenses of $9.0 million (down from $9.4M) and G&A expenses of $7.8 million (down from $8.5M). Net loss significantly improved to $0.4 million ($0.23 per share) compared to $15.5 million ($18.62 per share) in the previous year.
Neuphoria Therapeutics (NASDAQ:NEUP) has reached its target enrollment of 332 participants in the AFFIRM-1 Phase 3 clinical trial for BNC-210, their lead candidate for treating Social Anxiety Disorder (SAD). The trial is evaluating BNC-210 as a first-in-class, acute, "as needed", fast-acting treatment for SAD.
The company expects to release topline data in early Q4 2025. This milestone marks a significant step toward completing their first Phase 3 trial for BNC-210, positioning the company closer to potential regulatory submission if results are positive.
Neuphoria Therapeutics (Nasdaq: NEUP), a clinical-stage biotech company focused on neuropsychiatric disorder treatments, has announced its participation in the upcoming H.C. Wainwright 27th Annual Global Investment Conference.
The company's President and CEO, Dr. Spyros Papapetropoulos, will deliver a presentation at the conference, which takes place September 8-10, 2025 in New York. The presentation will be available on-demand starting September 5, 2025, at 7:00 a.m. ET, accessible through both the conference platform and Neuphoria's investor relations website.
Neuphoria Therapeutics (Nasdaq: NEUP), a clinical-stage biotech company focused on neuropsychiatric treatments, announced its upcoming presentation at the ASCP 2025 Annual Meeting. The company's President and CEO, Dr. Spyros Papapetropoulos, will present a pharmacokinetic/pharmacodynamic analysis of the BNC210 Attune Phase 2b dataset, which will help determine dosing for a planned Phase 3 PTSD study. The presentation is scheduled for May 28, 2025, from 3:40-4:00 pm MST at the Fairmont Scottsdale Princess in Arizona.
FAQ
What is the current stock price of Neuphoria Therapeutics (NEUP)?
What is the market cap of Neuphoria Therapeutics (NEUP)?
